Transactional
The years 2022 and 2023 presented significant challenges for the industry, with a post-pandemic market correction and macroeconomic pressures resulting in one of the worst performances in
decades. Depreciations made capital raising difficult for both private and publicly traded companies, reflecting in the transactional landscape of 2023.
As we enter 2024, the pharmaceutical industry faces unprecedented challenges. Market volatility remains high, driven by changes in capital dynamics and geopolitical issues, global inflation, and economic uncertainties. Sector-specific issues such as talent competition, politicization of drug pricing, healthrelated litigation, diversification in clinical trials, and the growing pressure environmental, social, and governance (ESG) issues may make the horizon difficult to perceive with the necessary clarity. Nevertheless, the new year…
